Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

25. Juli 2022 08:40 ET | Quelle: CMI

Global Achondroplasia Market to Surpass US$ 1,100.97 Million by 2030, Says Coherent Market Insights (CMI)

seattle, July 25, 2022 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the global achondroplasia market is estimated to be valued at US$ 93.82 million in 2022 and is expected to exhibit a...
12. Dezember 2016 08:29 ET | Quelle: BioMarin Pharmaceutical Inc.

BioMarin Enrolls First Participant in Phase 3 Trial of Vosoritide for Treatment of Children with Achondroplasia

SAN RAFAEL, Calif., Dec. 12, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today that the company has initiated a global Phase 3 study for vosoritide, an analog of...
19. Oktober 2016 17:01 ET | Quelle: BioMarin Pharmaceutical Inc.

BioMarin Presents Vosoritide Data in Achondroplasia at American Society of Human Genetics (ASHG) 2016 Meeting

Highest Dose (30 µg/kg/day) Shows Approximately 50% Increase in Mean Annualized Growth Velocity, Comparable with 15 µg/kg/day dose Consistent Safety Profile at High Dose Findings Support 15...
20. April 2016 10:36 ET | Quelle: BioMarin Pharmaceutical Inc.

BioMarin Provides Program Update on Vosoritide in Achondroplasia

New Data Shows Durable and Consistent Effects on Mean Annualized Growth Velocityfor up to 12 months with Increases of 46%-65% from Baseline Phase 3 Randomized Controlled Study Planned to Start at...